Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-324-3 | CAS number: 27206-35-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable well-documented publication which meets basic scientific principles.
- Remarks:
- read-across
- Justification for type of information:
- REPORTING FORMAT FOR THE CATEGORY APPROACH
For details, please refer to the attached read-across justification. In brief:
1. HYPOTHESIS FOR THE CATEGORY APPROACH (ENDPOINT LEVEL)
There are two category approaches relevant for all human health associated endpoints: Chain-length category and similar metabolic pathway.
Chain-length Category: Both SPS and Dimesna are sodium salts of two sulphonated alkanes connected via a disulphide group. SPS contains two propane moieties, Dimesna ethane ones, hence, these chemicals only differ minor in their hydrocarbon chains in one –CH2– group. The same applies to the carbon chain in MPS and MESNA, connecting the sodium sulfonate with the sulfhydryl moiety. The reactivity and toxicological relevance of this difference in chain length is considered to be minor compared to the chemicals properties triggered by the two remaining respective functional groups. Comparing the actually available information on the substances with regard to their physico-chemical properties, the minor influence of the hydrocarbon chain length becomes obvious. The melting points for the disulphide compounds and the sulfhydryl ones are consistent, and the ones for the ethane derivatives are as expected slightly lower. All compounds are very soluble in water, and similar consistencies are noted with regard to vapour pressure and partition coefficient.
Metabolic pathway: Here it is aimed to justify the read-across from both MPS to SPS and Mensa to Dimesna, and Dimesna to SPS and Mesna to MPS (and vice versa) based on the available information on their metabolism.
Generally, Mesna and Dimesna are considered to be a metabolite of each other. Also, other metabolites of Mesna were identified, besides Mesna-Mesna (i.e., Dimesna), such as Mesna-Cys, Mesna-homocysteine, Mesna-cysteinylglutamate, Mesna-cysteinylglycine, and Mesna-GSH which have been collectively termed “Dimesna” in some studies, while others refer to the mixed disulfides containing a single Mesna moiety as “Mesna”, quantifying Dimesna separately. The relevant functional groups for the enzymatic and non-enzymatic metabolism of Dimesna and Mesna are the disulphide resp. thiol functional groups. Those are both contained in the related substances SPS and MPS, which only differ from the former in their hydrocarbon chains in one –CH2– group, the basic structure and functional groups are however identical. Hence, only taking into account the given functional groups, a similar toxicodynamic behaviour of SPS and MPS compared to Dimesna and Mesna can be expected.
2. CATEGORY APPROACH JUSTIFICATION (ENDPOINT LEVEL)
As shown above, Mesna, MPS, Dimesna and SPS can be used for read-across to each other by grouping of chemicals. Mesna and MPS and Dimesna and SPS share similar physico-chemical properties as well as they exhibit similar toxicological properties, where data is available. Their alkyl side chains differ only in one –CH2- group, so it can be concluded that e.g. absorption, distribution patterns, or excretion from organ systems and body are comparable. Furthermore, Dimesna and Mesna are considered a metabolite of each other, which allows the conclusion that the same also applies for SPS and MPS. Conclusively, data for Mesna, MPS, and Dimesna can be used to cover data gaps for SPS; especially for the required endpoints for human health assessment.
Freely available toxicological information on Dimesna is lacking, so the available information on SPS, MPS and Mesna will be compared in order to obtain contributing information for the read-across justification, as set out in the attachment
The available data indicate that SPS, MPS and Mesna do not need to be classified as acute toxic according to Regulation (EC) No 1272/2008, all available LD50 (oral or dermal) values are greater than 2000 mg/kg bw, clearly indicating the comparability of the substances and the relative harmlessness of all group members including the target chemical SPS with regard to acute toxicity.
All available Ames tests on SPS, MPS and Mesna are consistently negative. Furthermore, the available in vitro micronucleus test on MPS, the SCE assay and in vivo micronucleus test on Mesna do also not give any indication that this group of substances bears any genotoxic properties. Here, gene mutation as well as chromosome mutation and clastogenicity endpoints are covered. In addition, the SCE assay is indicative for an enhanced repair activity upon genotoxic damage, which may result in several outcomes, e.g. point mutations, chromosome breaks etc., which support additionally the hypothesis that this group does not bear genotoxic properties of any kind.
In the available publications on carcinogenicity, both Mesna and its dimer Dimesna did not trigger any signs of toxicity or carcinogenic activity up to the highest dose tested, i.e., 15 resp. 35 mg/kg bw/d with lifetime exposure. Data on Mesna alone indicate that both doses could have been chosen much higher without resulting in any effects, as e.g. a NOAEL was determined to be 350 mg/kg bw/d over an exposure period of 39 weeks. Again this indicates that this group of chemicals does not trigger any relevant adverse effects upon repeated dosage. Last but not least, Mesna was not identified to be a developmental and or reproductive toxicant in several available studies on that endpoint, up to and including limit dosages of 2000 mg/kg bw/d.
Data source
Reference
- Reference Type:
- publication
- Title:
- Studies on the Urotoxicity of Oxazaphosphorine Cytostatics and its Prevention. 2. Comparative Study on the Uroprotective Efficacy of Thiols and Other Sulfur Compounds
- Author:
- Brock, N., Pohl, J., Stekar, J.
- Year:
- 1 981
- Bibliographic source:
- Eur J. Cancer Clin. Oncol., Vol. 17, No. 11, pp, 1155-1163, 1981.
Materials and methods
- Objective of study:
- excretion
- other: protective efficacy against ifosfamide induced urotoxicity
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Mesna was tested for its uroprotective efficacy in 10 (per dose level) Sprague Dawley rats treated with 68 mg/kg ifosfamide that is known to induce haemorrhagic cystitis. Mesna was administered by i. v. administration 15 min before the injection of ifosfamide at dose levels of 6.81, 10.0, 14.7 and 21.5 mg/kg bw. The uroprotective efficacy of Mesna was evaluated 24 hours after the administration of ifosfamide. The rats were killed and the urinary bladder were evaluated (inflammation, bleeding and weight). The pharmakokinetic behaviour of mesna was also studied.
- GLP compliance:
- no
Test material
- Reference substance name:
- Disodium 3,3'-dithiobis[propanesulphonate]
- EC Number:
- 248-324-3
- EC Name:
- Disodium 3,3'-dithiobis[propanesulphonate]
- Cas Number:
- 27206-35-5
- Molecular formula:
- C6H14O6S4.2Na
- IUPAC Name:
- disodium 3,3'-disulfanediyldipropane-1-sulfonate
- Test material form:
- solid
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Asta-Werke, Bielefeld, and Mus Rattus AG, Brunnthal
- Weight at study initiation: 250 g
- Housing: standard conditions
- Diet (e.g. ad libitum): ad libitum (altromin ® 1324, no deprivation)
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS: not reported
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- physiological saline
- Details on exposure:
- No details reported
- Duration and frequency of treatment / exposure:
- single treatment
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Screening dose: 100 mg/kg bw;
Further doses: 6.81, 10.0, 14.7 and 21.5 mg/kg bw
- No. of animals per sex per dose / concentration:
- 10
- Control animals:
- yes, concurrent no treatment
- Positive control reference chemical:
- Ifosfamide (68 mg/kg bw)
- Details on study design:
- - Dose selection rationale: screening dose 100 mg/kg, raised or lowered in steps with a factor of 2.15.
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (excretion)
- Tissues and body fluids sampled: urine
- Time and frequency of sampling: not reported in details (most likely: every hour) - Statistics:
- No data
Results and discussion
Main ADME results
- Type:
- excretion
- Results:
- After i.v. administration of 21.5 mg/kg to the rat, about 40% of the administered dose is excreted with the urine as the sulfhydryl compound within the first hour.
Toxicokinetic / pharmacokinetic studies
- Details on excretion:
- Within the first 3 hour about 50% of the dose is excreted as the sulfhydryl compound and a further 30% of the dose as the disulphide. Rapid renal excretion of sulfhydryl groups is also observed after oral administration of mesna to rats. Similar findings have also been made on the dog. The behaviour of dimesna after intravenous and after oral administration to rats and dogs is very similar to that of mesna. After i.v. administration of 42.4 mg/kg to rats, 28% of the dose was excreted with the urine as the free sulfhydryl compound within 3 hours.
Any other information on results incl. tables
The severity of the inflammation of the bladder after i.v. administration of ifosfamide was dose-dependent. An ifosfamide dose of 68 mg/kg always induced an approximately 2- fold increase in the wet weight of the bladder and a damage score of about 2. Some of the rats also showed bladder haemorrhages. The scoring system used takes into account two parameters: firstly, increased capillary permeability (which is demonstrable objectively by the extravasal occurrence of intravenously injected trypan blue) and secondly, the increase in the weight of the bladder, which can also be assessed macroscopically as a swelling of the bladder. In some selected groups the bladder damage and the extent of bladder protection were also investigated histologically. The uroprotective effect of mesna was dose-dependent. It was reflected in a reduced increase in the bladder weight and reduced extravasation of trypan blue, and it was also demonstrable histologically. In the case of mesna, the lowest dose ensuring reliable uroprotection was determined. The results of these investigations of the uroprotective efficacy of MPS and mesna (as well as it dimer dimesna) are summarized in the following table:
Table 1. Uroprotective action of mercapto-alkane sulfonates and analogues | |||||||||
Assessment of urinary bladder | |||||||||
Compound | Structural formula | Dose (mg/kg) | Animals (n) | Inflamm. (x/n) | Bleeding | Weight (mg) | Score (0-3) | ||
x/n | Mean+S.E. | ||||||||
Untreated controls | — | 105 | 0 | 0 | 81.0±12.0 | 0 | |||
Ifosfamide | 68.1 | i.v. | 100 | 100 | 63 | 165.0±35.0 | 2.3 | ||
Mesna | HS-CH2-CH2 -SO3Na | 6.81 | i.v. | 10 | 6 | 1 | 97.3±22.6 | 1.5 | |
10.0 | i.v. | 10 | 2 | 0 | 88.8±5.4 | 0.5 | |||
14.7 | i.v. | 10 | 0 | 0 | 77.5±10.9 | 0.3 | |||
21.5 | i.v. | 10 | 0 | 0 | 72.6±10.3 | 0 | |||
Dimesna | S-CH2CH2-S03Na S-CH2CH2-S03Na |
21.5 | i.v. | 10 | 6 | 3 | 137.5±29.1 | 1.4 | |
31.6 | i.v. | 10 | 3 | 0 | 101.6±12.4 | 0.3 | |||
46.4 | i.v. | 10 | 1 | 0 | 86.6±12.4 | 0.1 | |||
68.1 | i.v. | 10 | 0 | 0 | 77.5±10.9 | 0 | |||
Asta 7100 | HS-(CH2)3-SO3Na | 21.5 | i.v. | 5 | 5 | 0 | 138.4±26.5 | 2.0 | |
68.1 | i.v. | 5 | 3 | 0 | 80.4±7.4 | 0.5 | |||
215.0 | i.v. | 5 | 1 | 0 | 77.0±10.1 | 0.1 |
The longer chain homologue of mesna, Asta 7100 (= MPS), was also effective in protection of urinary bladder against ifosfamide induced urotoxicity.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results: no bioaccumulation potential based on study results
Mesna protected completely ifosfamide induced urotoxicity in rats. Mesna was rapidly excreted in the urine. Data is taken from an acceptable well documented publication which meets basic scientific principles on a suitable Read-Across substance. Hence, data can be considered to be reliable within an WoE approach to conclude that no potential to bioaccumulate is given for Mesna or its category members. - Executive summary:
Mesna was tested for its uroprotective efficacy in 10 (per dose level) Sprague Dawley rats treated with 68 mg/kg ifosfamide that is known to induce haemorrhagic cystitis (Brock et al., 1981). Mesna was administered by i. v. administration 15 min before the injection of ifosfamide at dose levels of 6.81, 10.0, 14.7 and 21.5 mg/kg bw. The uroprotective efficacy of Mesna was evaluated 24 hours after the administration of ifosfamide. The rats were killed and the urinary bladder were evaluated (inflammation, bleeding and weight). The pharmakokinetic behaviour of mesna was also studied.
The severity of the inflammation of the bladder after i.v. administration of ifosfamide was dose-dependent. An ifosfamide dose of 68 mg/kg always induced an approximately 2- fold increase in the wet weight of the bladder and a damage score of about 2. Some of the rats also showed bladder haemorrhages. The scoring system used takes into account two parameters: firstly, increased capillary permeability (which is demonstrable objectively by the extravasal occurrence of intravenously injected trypan blue) and secondly, the increase in the weight of the bladder, which can also be assessed macroscopically as a swelling of the bladder. In some selected groups the bladder damage and the extent of bladder protection were also investigated histologically. The uroprotective effect of mesna was dose-dependent. It was reflected in a reduced increase in the bladder weight and reduced extravasation of trypan blue, and it was also demonstrable histologically. In the case of mesna, the lowest dose ensuring reliable uroprotection was determined (10 mg/kg bw). The longer chain homologue of mesna, MPS, the proposed metabolite of SPS, was also effective in protection of urinary bladder against ifosfamide induced urotoxicity. Regrading excretion of mesna, after i.v. administration of 21.5 mg/kg to the rat, about 40% of the administered dose is excreted with the urine as the sulfhydryl compound within the first hour. Within the first 3 hour about 50% of the dose is excreted as the sulfhydryl compound and a further 30% of the dose as the disulfide. Rapid renal excretion of sulfhydryl groups is also observed after oral administration of mesna to rats. Similar findings have also been made on the dog. The behaviour of dimesna after intravenous and after oral administration to rats and dogs is very similar to that of mesna. After i.v. administration of 42.4 mg/kg to rats, 28% of the dose was excreted with the urine as the free sulfhydryl compound within 3 hours.
Mesna is a suitable Read-Across substance for SPS asDimesna and Mesna could be considered a metabolite of each other, which allows the conclusion that the same also applies for SPS and MPS, and their respective alkyl side chains differ only in one –CH2- group, so it can reasonably concluded that e.g. absorption, distribution patterns, or excretion from organ systems and body in total are comparable, which is in detail outlined in the read-across justification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.